Neogenomics IncNASDAQ:NEO
- LAST PRICE13.5100
- TODAY'S CHANGE (%)0.4400 (3.3665%)
- Bid / Lots13.4800/ 6
- Ask / Lots13.5200/ 6
- Open / Previous Close13.1700 / 13.0700
- Day Range
- 52 Week Range
- Volume49,113
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | NEO |
|---|---|---|
| 09:32 ET | 4107 | 13.17 |
| 09:34 ET | 1672 | 13.24 |
| 09:36 ET | 420 | 13.2301 |
| 09:38 ET | 600 | 13.28 |
| 09:39 ET | 300 | 13.285 |
| 09:41 ET | 1180 | 13.36 |
| 09:43 ET | 100 | 13.41 |
| 09:45 ET | 300 | 13.42 |
| 09:48 ET | 285 | 13.41 |
| 09:50 ET | 482 | 13.43 |
| 09:52 ET | 437 | 13.4399 |
| 09:54 ET | 2873 | 13.5 |
| 09:56 ET | 4521 | 13.49 |
| 09:57 ET | 1186 | 13.49 |
| 09:59 ET | 3012 | 13.505 |
| 10:01 ET | 1817 | 13.475 |
| 10:03 ET | 4950 | 13.47 |
| 10:06 ET | 3945 | 13.48 |
| 10:08 ET | 876 | 13.525 |
| 10:10 ET | 100 | 13.525 |
| 10:12 ET | 400 | 13.51 |
| 10:14 ET | 728 | 13.5 |
| 10:15 ET | 100 | 13.51 |
Oct 22, 2024
NeoGenomics Receives New York State Approval for Neo Comprehensive(TM) Solid Tumor Test, from 8:10AM ET on Tuesday Oct 22, 2024 by Dow Jones
8:10AM ET on Tuesday Oct 22, 2024 by Dow Jones
Oct 15, 2024
Press Release: NeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024, from 7:47AM ET on Tuesday Oct 15, 2024 by Dow Jones
7:47AM ET on Tuesday Oct 15, 2024 by Dow JonesNeoGenomics to Report Third Quarter 2024 Financial Results on Nov. 5, 2024, from 7:30AM ET on Tuesday Oct 15, 2024 by Dow Jones
7:30AM ET on Tuesday Oct 15, 2024 by Dow Jones
Oct 8, 2024
NeoGenomics Launches AML Express for Rapid Genetic Profiling of Acute Myeloid Leukemia, from 8:10AM ET on Tuesday Oct 08, 2024 by Dow Jones
8:10AM ET on Tuesday Oct 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Neogenomics Inc | 1.7B | -21.7x | --- |
GeneDx Holdings Corp | 1.6B | -13.4x | --- |
LTC Properties Inc | 1.5B | 16.3x | -11.14% |
National Healthcare Corp | 1.8B | 20.3x | +1.85% |
US Physical Therapy Inc | 1.2B | 77.6x | -0.50% |
Pennant Group Inc | 1.1B | 52.7x | -5.49% |
Company Information
NeoGenomics, Inc. provides a range of oncology diagnostic testing and consultative services which includes technical laboratory services. The Company offers professional interpretation of laboratory test results by licensed physicians who specialize in pathology and oncology. Its segments include Clinical Services and Advanced Diagnostics. The Clinical Services segment consists of clinical cancer testing; interpretation and consultative services; molecular and NGS testing, and comprehensive technical and professional services offering. Its Clinical Services customers include community-based pathology and oncology practices, hospital pathology labs, reference labs, and academic centers. The Advanced Diagnostics segment consist of clinical trials and research, validation laboratory services, and informatics. Its Advanced Diagnostics customers include pharmaceutical companies to whom it provides testing and other services to support their research studies and clinical trials.
Contact Information
- Headquarters
- 9490 Neogenomics WayFORT MYERS, FL, United States 33912
- Phone
- 239-768-0600
- Fax
- 775-329-0852
Executives
- Independent Chairman of the Board
- Lynn Tetrault
- Chief Executive Officer, Director
- Christopher Smith
- Chief Financial Officer
- Jeffrey Sherman
- President - Advanced Diagnostics
- Vishal Sikri
- Chief Operating Officer, President - Informatics
- Melody Harris
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $1.7B |
|---|---|
Revenue (TTM) | $628.2M |
Shares Outstanding | 128.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.18 |
EPS | $-0.62 |
Book Value | $7.39 |
P/E Ratio | -21.7x |
Price/Sales (TTM) | 2.7 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -15.17% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
